• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

带有内置 T 辅助表位的重组 SARS-CoV-2 RBD 诱导强烈的中和抗体反应。

Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response.

机构信息

National Institute For Viral Disease Control and Prevention, Chinese Center For Disease Control and Prevention, Beijing 102206, China.

Sinovac Biotech Co., Ltd, Beijing 100085, China.

出版信息

Vaccine. 2021 Feb 22;39(8):1241-1247. doi: 10.1016/j.vaccine.2021.01.044. Epub 2021 Jan 20.

DOI:10.1016/j.vaccine.2021.01.044
PMID:33516600
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7816590/
Abstract

Without approved vaccines and specific treatments, COVID-19 is spreading around the world with above 26 million cases and approximately 864 thousand deaths until now. An efficacious and affordable vaccine is urgently needed. The Val308 - Gly548 of spike protein of SARS-CoV-2 linked with Gln830 - Glu843 of Tetanus toxoid (TT peptide) (designated as S1-4) and without TT peptide (designated as S1-5) were expressed and renatured. The antigenicity and immunogenicity of S1-4 were evaluated by Western Blotting (WB) in vitro and immune responses in mice, respectively. The protective efficiency was measured preliminarily by microneutralization assay (MN50). The soluble S1-4 and S1-5 protein was prepared to high homogeneity and purity. Adjuvanted with Alum, S1-4 protein stimulated a strong antibody response in immunized mice and caused a major Th2-type cellular immunity supplemented with Th1-type immunity. Furthermore, the immunized sera could protect the Vero E6 cells from SARS-CoV-2 infection with neutralizing antibody titer 256. Recombinant SARS-CoV-2 RBD with a built in T helper epitope could stimulate both strong humoral immunity supplemented with cellular immunity in mice, demonstrating that it could be a promising subunit vaccine candidate.

摘要

截至目前，尚无经过批准的疫苗和特效疗法，全球新冠肺炎确诊病例已超过 2600 万例，死亡病例约 86.4 万例。目前急需研发出有效且可负担的疫苗。我们表达并复性了与破伤风类毒素（TT 肽）中 Gln830-Glu843 相连的 SARS-CoV-2 刺突蛋白的 Val308-Gly548（命名为 S1-4）和不含 TT 肽的 S1-5（命名为 S1-5）。我们分别通过 Western Blotting（WB）和小鼠免疫试验评估了 S1-4 的抗原性和免疫原性。通过微量中和试验（MN50）初步测定了保护效率。可溶性 S1-4 和 S1-5 蛋白高度均一且纯度较高。用 Alum 佐剂后，S1-4 蛋白在免疫小鼠中激发了强烈的抗体应答，并引起以 Th2 型细胞免疫为主、补充 Th1 型免疫的反应。此外，免疫血清能以中和抗体滴度 256 保护 Vero E6 细胞免受 SARS-CoV-2 感染。带有内置 T 辅助表位的重组 SARS-CoV-2 RBD 能在小鼠中刺激强烈的体液免疫和细胞免疫，表明它可能成为一种有前途的亚单位疫苗候选物。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a23/7816590/9d0a79e0ec84/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a23/7816590/6ac3fc572ec4/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a23/7816590/3f56656519bd/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a23/7816590/7a87940c22d5/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a23/7816590/c4e289f6e9ea/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a23/7816590/d1abe9451af7/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a23/7816590/9d0a79e0ec84/gr6_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a23/7816590/6ac3fc572ec4/gr1_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a23/7816590/3f56656519bd/gr2_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a23/7816590/7a87940c22d5/gr3_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a23/7816590/c4e289f6e9ea/gr4_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a23/7816590/d1abe9451af7/gr5_lrg.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/5a23/7816590/9d0a79e0ec84/gr6_lrg.jpg

相似文献

1
Recombinant SARS-CoV-2 RBD with a built in T helper epitope induces strong neutralization antibody response.带有内置 T 辅助表位的重组 SARS-CoV-2 RBD 诱导强烈的中和抗体反应。
Vaccine. 2021 Feb 22;39(8):1241-1247. doi: 10.1016/j.vaccine.2021.01.044. Epub 2021 Jan 20.
2
Preclinical evaluation of a synthetic peptide vaccine against SARS-CoV-2 inducing multiepitopic and cross-reactive humoral neutralizing and cellular CD4 and CD8 responses.针对 SARS-CoV-2 的合成肽疫苗的临床前评估，该疫苗可诱导多表位和交叉反应性体液中和以及细胞 CD4 和 CD8 反应。
Emerg Microbes Infect. 2021 Dec;10(1):1931-1946. doi: 10.1080/22221751.2021.1978823.
3
SARS-CoV-2 S1 is superior to the RBD as a COVID-19 subunit vaccine antigen.SARS-CoV-2 S1 作为 COVID-19 亚单位疫苗抗原优于 RBD。
J Med Virol. 2021 Feb;93(2):892-898. doi: 10.1002/jmv.26320. Epub 2020 Oct 5.
4
Adjuvanting a subunit COVID-19 vaccine to induce protective immunity.佐剂 COVID-19 亚单位疫苗以诱导保护性免疫。
Nature. 2021 Jun;594(7862):253-258. doi: 10.1038/s41586-021-03530-2. Epub 2021 Apr 19.
5
Elicitation of Broadly Neutralizing Antibodies against B.1.1.7, B.1.351, and B.1.617.1 SARS-CoV-2 Variants by Three Prototype Strain-Derived Recombinant Protein Vaccines.三种原型株衍生重组蛋白疫苗对 B.1.1.7、B.1.351 和 B.1.617.1 变异 SARS-CoV-2 诱导产生广谱中和抗体。
Viruses. 2021 Jul 22;13(8):1421. doi: 10.3390/v13081421.
6
α-Hemolysin-Aided Oligomerization of the Spike Protein RBD Resulted in Improved Immunogenicity and Neutralization Against SARS-CoV-2 Variants.α-溶血素辅助的刺突蛋白 RBD 寡聚化导致针对 SARS-CoV-2 变体的免疫原性和中和作用增强。
Front Immunol. 2021 Sep 24;12:757691. doi: 10.3389/fimmu.2021.757691. eCollection 2021.
7
SARS-CoV-2 spike produced in insect cells elicits high neutralization titres in non-human primates.昆虫细胞表达的 SARS-CoV-2 刺突蛋白可在非人灵长类动物中引起高中和抗体滴度。
Emerg Microbes Infect. 2020 Dec;9(1):2076-2090. doi: 10.1080/22221751.2020.1821583.
8
[Preparation and immungenicity of recombinant protein containing intramolecular adjuvant in SARS-CoV-2 RBD domain].[含分子内佐剂的新型冠状病毒受体结合域重组蛋白的制备及免疫原性]
Sheng Wu Gong Cheng Xue Bao. 2022 Sep 25;38(9):3353-3362. doi: 10.13345/j.cjb.210883.
9
A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.一种针对严重急性呼吸综合征冠状病毒 2 刺突蛋白 RBD 的疫苗可诱导保护性免疫。
Nature. 2020 Oct;586(7830):572-577. doi: 10.1038/s41586-020-2599-8. Epub 2020 Jul 29.
10
Development of a Recombinant RBD Subunit Vaccine for SARS-CoV-2.开发一种用于 SARS-CoV-2 的重组 RBD 亚单位疫苗。
Viruses. 2021 Sep 26;13(10):1936. doi: 10.3390/v13101936.

引用本文的文献

1
Enhancement of immunogenicity of SARS-CoV-2 spike protein expressed in by fusion of the CRM197 functional domain.通过CRM197功能域融合增强在[具体表达体系]中表达的SARS-CoV-2刺突蛋白的免疫原性。 （注：原文中“by fusion of the CRM197 functional domain”前缺少表达体系相关内容，翻译时补充了[具体表达体系]使句子逻辑完整）
Front Microbiol. 2025 Aug 12;16:1650239. doi: 10.3389/fmicb.2025.1650239. eCollection 2025.
2
RBD-displaying OMV nanovaccine boosts immunity against SARS-CoV-2.展示RBD的外膜囊泡纳米疫苗增强对SARS-CoV-2的免疫力。
J Nanobiotechnology. 2025 Feb 8;23(1):97. doi: 10.1186/s12951-025-03191-7.
3
Semisynthesis of homogeneous spike RBD glycoforms from SARS-CoV-2 for profiling the correlations between glycan composition and function.

本文引用的文献

1
A Novel Coronavirus Genome Identified in a Cluster of Pneumonia Cases - Wuhan, China 2019-2020.在中国武汉2019 - 2020年肺炎病例群中发现的一种新型冠状病毒基因组
China CDC Wkly. 2020 Jan 24;2(4):61-62.
2
Yeast-expressed SARS-CoV recombinant receptor-binding domain (RBD219-N1) formulated with aluminum hydroxide induces protective immunity and reduces immune enhancement.酵母表达的 SARS-CoV 重组受体结合域（RBD219-N1）与氢氧化铝配制而成，可诱导保护性免疫，并降低免疫增强作用。
Vaccine. 2020 Nov 3;38(47):7533-7541. doi: 10.1016/j.vaccine.2020.09.061. Epub 2020 Sep 22.
3
A single dose of an adenovirus-vectored vaccine provides protection against SARS-CoV-2 challenge.
从严重急性呼吸综合征冠状病毒2（SARS-CoV-2）进行同源刺突受体结合域糖型的半合成，以分析聚糖组成与功能之间的相关性。
Natl Sci Rev. 2024 Jan 22;11(2):nwae030. doi: 10.1093/nsr/nwae030. eCollection 2024 Feb.
4
Antibody Response Following the Intranasal Administration of SARS-CoV-2 Spike Protein-CpG Oligonucleotide Vaccine.鼻内接种新型冠状病毒刺突蛋白-CpG寡核苷酸疫苗后的抗体反应
Vaccines (Basel). 2023 Dec 20;12(1):5. doi: 10.3390/vaccines12010005.
5
RSV pre-fusion F protein enhances the G protein antibody and anti-infectious responses.呼吸道合胞病毒融合前F蛋白增强G蛋白抗体和抗感染反应。
NPJ Vaccines. 2022 Dec 19;7(1):168. doi: 10.1038/s41541-022-00591-w.
6
Engineering probiotic-derived outer membrane vesicles as functional vaccine carriers to enhance immunity against SARS-CoV-2.工程化益生菌衍生的外膜囊泡作为功能性疫苗载体以增强对SARS-CoV-2的免疫力。
iScience. 2023 Jan 20;26(1):105772. doi: 10.1016/j.isci.2022.105772. Epub 2022 Dec 8.
7
Two formulations of coronavirus disease-19 recombinant subunit vaccine candidate made up of S1 fragment protein P1, S2 fragment protein P2, and nucleocapsid protein elicit strong immunogenicity in mice.两种由 S1 片段蛋白 P1、S2 片段蛋白 P2 和核衣壳蛋白组成的新型冠状病毒病-19 重组亚单位疫苗候选物在小鼠中引发强烈的免疫原性。
Immun Inflamm Dis. 2022 Dec;10(12):e748. doi: 10.1002/iid3.748.
8
Enhancing the Immunogenicity of RBD Protein Variants through Amino Acid E484 Mutation in SARS-CoV-2.通过 SARS-CoV-2 中 E484 氨基酸突变增强 RBD 蛋白变异体的免疫原性。
Viruses. 2022 Sep 13;14(9):2020. doi: 10.3390/v14092020.
9
The Occluded Epitope Residing in Spike Receptor-Binding Motif Is Essential for Cross-Neutralization of SARS-CoV-2 Delta Variant.位于刺突受体结合基序中的封闭表位对于SARS-CoV-2 Delta变体的交叉中和至关重要。
Curr Issues Mol Biol. 2022 Jun 29;44(7):2842-2855. doi: 10.3390/cimb44070195.
10
Addition of arginine hydrochloride and proline to the culture medium enhances recombinant protein expression in Brevibacillus choshinensis: The case of RBD of SARS-CoV-2 spike protein and its antibody.在培养基中添加盐酸精氨酸和脯氨酸可增强短小芽孢杆菌中重组蛋白的表达：以 SARS-CoV-2 刺突蛋白的 RBD 及其抗体为例。
Protein Expr Purif. 2022 Jun;194:106075. doi: 10.1016/j.pep.2022.106075. Epub 2022 Feb 26.
一剂腺病毒载体疫苗可提供针对 SARS-CoV-2 挑战的保护。
Nat Commun. 2020 Aug 14;11(1):4081. doi: 10.1038/s41467-020-17972-1.
4
Development of an Inactivated Vaccine Candidate, BBIBP-CorV, with Potent Protection against SARS-CoV-2.开发一种具有强大预防 SARS-CoV-2 能力的灭活疫苗候选物，BBIBP-CorV。
Cell. 2020 Aug 6;182(3):713-721.e9. doi: 10.1016/j.cell.2020.06.008. Epub 2020 Jun 6.
5
SARS-CoV-2 mRNA vaccine design enabled by prototype pathogen preparedness.通过原型病原体准备实现的 SARS-CoV-2 mRNA 疫苗设计。
Nature. 2020 Oct;586(7830):567-571. doi: 10.1038/s41586-020-2622-0. Epub 2020 Aug 5.
6
A vaccine targeting the RBD of the S protein of SARS-CoV-2 induces protective immunity.一种针对严重急性呼吸综合征冠状病毒 2 刺突蛋白 RBD 的疫苗可诱导保护性免疫。
Nature. 2020 Oct;586(7830):572-577. doi: 10.1038/s41586-020-2599-8. Epub 2020 Jul 29.
7
Immunogenicity and safety of a recombinant adenovirus type-5-vectored COVID-19 vaccine in healthy adults aged 18 years or older: a randomised, double-blind, placebo-controlled, phase 2 trial.重组 5 型腺病毒载体 COVID-19 疫苗在 18 岁及以上健康成年人中的免疫原性和安全性：一项随机、双盲、安慰剂对照、2 期临床试验。
Lancet. 2020 Aug 15;396(10249):479-488. doi: 10.1016/S0140-6736(20)31605-6. Epub 2020 Jul 20.
8
Immune and bioinformatics identification of T cell and B cell epitopes in the protein structure of SARS-CoV-2: A systematic review.免疫和生物信息学鉴定 SARS-CoV-2 蛋白结构中的 T 细胞和 B 细胞表位：系统评价。
Int Immunopharmacol. 2020 Sep;86:106738. doi: 10.1016/j.intimp.2020.106738. Epub 2020 Jun 28.
9
A Universal Design of Betacoronavirus Vaccines against COVID-19, MERS, and SARS.通用设计的贝塔冠状病毒疫苗，用于预防 COVID-19、MERS 和 SARS。
Cell. 2020 Aug 6;182(3):722-733.e11. doi: 10.1016/j.cell.2020.06.035. Epub 2020 Jun 28.
10
Immunoinformatic Analysis of T- and B-Cell Epitopes for SARS-CoV-2 Vaccine Design.用于SARS-CoV-2疫苗设计的T细胞和B细胞表位的免疫信息学分析
Vaccines (Basel). 2020 Jul 3;8(3):355. doi: 10.3390/vaccines8030355.